{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T04:05:01Z","timestamp":1742789101094,"version":"3.40.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Oral Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>There is growing literature related to the dental effects of biologic agents. However, little research has evaluated the dental needs of these patients and limited data is available on patients taking vascular endothelial growth factor (VEGF) antagonists.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>This retrospective cross-sectional study analyzed patients taking VEGF antagonists and their respective dental treatments from 2017 to 2023. Patient demographics, decayed, missing, and filled tooth (DMFT) status, and treatment details were recorded and evaluated descriptively. DMFT from this population was compared to patients taking other biologic agents using t-tests.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Twenty-three patients taking VEGF antagonists received dental treatment. Periodontal treatments were the most common (<jats:italic>n<\/jats:italic>\u2009=\u200918, 78%), followed by restorative treatments (<jats:italic>n<\/jats:italic>\u2009=\u200917, 74%). DMFT data for patients taking VEGF antagonists were not significantly different than values for patients taking other biologic agents, except for patients taking TNF-\u03b1 Inhibitors, who had significantly fewer missing teeth than patients taking VEGF antagonists (3.88 vs. 8.10, <jats:italic>p<\/jats:italic>\u2009=\u20090.01).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The necessity of dental treatment in patients taking VEGF Antagonists is still unknown. Periodontal and restorative treatments were the most common modalities with no complications observed from treatment. While preventive periodontal treatment is routinely recommended, high usage of targeted periodontal and restorative treatments is seen in this population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical relevance<\/jats:title>\n            <jats:p>Minimal evidence exists to date on the delivery of and need for routine dental treatment among patients taking VEGF antagonists. This paper presents a first estimate of dental needs in this population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00784-025-06230-7","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T03:29:32Z","timestamp":1740194972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective, cross-sectional analysis of the dental status and needs of patients taking vascular endothelial growth factor (VEGF) antagonists"],"prefix":"10.1007","volume":"29","author":[{"given":"Alexander","family":"Raucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8787-9972","authenticated-orcid":false,"given":"Katherine","family":"France","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"key":"6230_CR1","unstructured":"National Cancer Institute (2021) Definition of biologic agent. NCI Dictionary of Cancer Terms. Accessed July 27, 2023. https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/biologic-agent"},{"key":"6230_CR2","volume-title":"Contemporary oral medicine: a Comprehensive Approach to Clinical Practice","author":"CS Farah","year":"2020","unstructured":"Farah CS, Balasubramaniam R, McCullough MJ (2020) Contemporary oral medicine: a Comprehensive Approach to Clinical Practice. Springer Nature Switzerland, Cham, Switzerland"},{"key":"6230_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-1-4419-9148-5-13","volume-title":"VEGF and Cancer","author":"AM Duffy","year":"2011","unstructured":"Duffy AM, Bouchier-Hayes DJ, Harmey JH (2011) Vascular endothelial growth factor (VEGF) and its role in non-endothelial cells: autocrine signaling by VEGF. In: Harmey J (ed) VEGF and Cancer. Springer-, New York, pp 133\u2013144. https:\/\/doi.org\/10.1007\/978-1-4419-9148-5-13"},{"key":"6230_CR4","unstructured":"National Cancer Institute (2021) Definition of VEGF-AS. NCI Dictionary of Cancer Terms. https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/vegf-as. Accessed July 27, 2023"},{"key":"6230_CR5","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB et al (2020) Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102017","journal-title":"Cancer Treat Rev"},{"key":"6230_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/s0079-6123(09)17517-9","volume":"175","author":"RO Schlingemann","year":"2009","unstructured":"Schlingemann RO, Witmer AN (2009) Treatment of retinal diseases with VEGF antagonists. Prog Brain Res 175:253\u2013267. https:\/\/doi.org\/10.1016\/s0079-6123(09)17517-9","journal-title":"Prog Brain Res"},{"issue":"6","key":"6230_CR7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1172\/jci15153","volume":"110","author":"H Peng","year":"2002","unstructured":"Peng H, Wright V, Usas A et al (2002) Synergistic enhancement of bone formation and healing by stem cell\u2013expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110(6):751\u2013759. https:\/\/doi.org\/10.1172\/jci15153","journal-title":"J Clin Invest"},{"issue":"s1","key":"6230_CR8","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1111\/j.1440-1746.2010.06222.x","volume":"25","author":"K Takeuchi","year":"2010","unstructured":"Takeuchi K, Tanigami M, Amagase K, Ochi A, Okuda S, Hatazawa R (2010) Endogenous prostaglandin E2 accelerates healing of indomethacin-induced small intestinal lesions through upregulation of vascular endothelial growth factor expression by activation of EP4 receptors. J Gastroenterol Hepatol 25(s1):S67\u201374. https:\/\/doi.org\/10.1111\/j.1440-1746.2010.06222.x","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"6230_CR9","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1359\/jbmr.050708","volume":"20","author":"H Peng","year":"2005","unstructured":"Peng H, Usas A, Olshanski A et al (2005) VEGF improves, whereas SFLT1 inhibits, BMP2-induced bone formation and bone healing through modulation of angiogenesis. J Bone Min Res 20(11):2017\u20132027. https:\/\/doi.org\/10.1359\/jbmr.050708","journal-title":"J Bone Min Res"},{"key":"6230_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/opth.s29075","volume":"6","author":"A Mansour","year":"2012","unstructured":"Mansour A (2012) Insight into 144 patients with ocular vascular events during VEGF antagonist injections. Clin Ophthalmol 6:343\u2013363. https:\/\/doi.org\/10.2147\/opth.s29075","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"6230_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00784-016-1937-6","volume":"21","author":"Y Manor","year":"2016","unstructured":"Manor Y, Simon R, Haim D, Garfunkel A, Moses O (2016) Dental implants in medically complex patients\u2014a retrospective study. Clin Oral Investig 21(2):701\u2013708. https:\/\/doi.org\/10.1007\/s00784-016-1937-6","journal-title":"Clin Oral Investig"},{"key":"6230_CR12","unstructured":"American Dental Association (2025) CDT 2025: Current Dental Terminology American Dental Association, Chicago"},{"key":"6230_CR13","unstructured":"Centers for Disease Control and Prevention (2024) Oral Health Surveillance Report: Dental Caries, Tooth Retention, and Edentulism, United States, 2017\u2013March 2020. U.S. Dept of Health and Human Services. https:\/\/www.cdc.gov\/oral-health\/php\/2024-oralhealth-surveillance-report\/. Accessed February 7,2025"},{"issue":"5","key":"6230_CR14","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s10637-015-0283-x","volume":"33","author":"T Tabouret","year":"2015","unstructured":"Tabouret T, Gregory T, Dhooge M et al (2015) Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosis. Invest New Drugs 33(5):1144\u20131147. https:\/\/doi.org\/10.1007\/s10637-015-0283-x","journal-title":"Invest New Drugs"},{"issue":"4","key":"6230_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10006-012-0379-9","volume":"17","author":"D Pakosch","year":"2012","unstructured":"Pakosch D, Papadimas D, Munding J, Kawa D, Kriwalsky MS (2012) Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral Maxillofa Surg 17(4):303\u2013306. https:\/\/doi.org\/10.1007\/s10006-012-0379-9","journal-title":"Oral Maxillofa Surg"},{"issue":"1","key":"6230_CR16","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.4317\/medoral.23191","volume":"25","author":"A Eguia","year":"2020","unstructured":"Eguia A, Bag\u00e1n-Deb\u00f3n L, Cardona F (2020) Review and update on drugs related to the development of osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal 25(1):e71\u2013e83. https:\/\/doi.org\/10.4317\/medoral.23191","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"3","key":"6230_CR17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bjoms.2016.11.315","volume":"55","author":"P Zarringhalam","year":"2017","unstructured":"Zarringhalam P, Brizman E, Shakib K (2017) Medication-related osteonecrosis of the jaw associated with aflibercept. Br J Oral Maxillofac Surg 55(3):314\u2013315. https:\/\/doi.org\/10.1016\/j.bjoms.2016.11.315","journal-title":"Br J Oral Maxillofac Surg"},{"key":"6230_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12903-015-0047-1","volume":"15","author":"T Zhu","year":"2015","unstructured":"Zhu T, Park HC, Son KM, Yang H-C (2015) Effects of dimethyloxalylglycine on wound healing of palatal mucosa in a rat model. BMC Oral Health 15:60. https:\/\/doi.org\/10.1186\/s12903-015-0047-1","journal-title":"BMC Oral Health"},{"issue":"3","key":"6230_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.14744\/eej.2018.07269","volume":"3","author":"LT Friedlander","year":"2018","unstructured":"Friedlander LT, Coats D, Seymour G, Cullinan M, Rich AR (2018) Vascularity and VEGF\/VEGFR2 signaling in the dentine-pulp complex of immature and mature permanent teeth. Eur Endod J 3(3):153\u2013159. https:\/\/doi.org\/10.14744\/eej.2018.07269","journal-title":"Eur Endod J"},{"key":"6230_CR20","doi-asserted-by":"publisher","first-page":"10860","DOI":"10.1038\/s41598-019-47221-5","volume":"9","author":"CM Franca","year":"2019","unstructured":"Franca CM, Riggers R, Muschler JL et al (2019) 3D-imaging of whole neuronal and vascular networks of the human dental pulp via CLARITY and light sheet microscopy. Sci Rep 9:10860. https:\/\/doi.org\/10.1038\/s41598-019-47221-5","journal-title":"Sci Rep"},{"issue":"2","key":"6230_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.14744\/eej.2019.26349","volume":"4","author":"A Al-Hassiny","year":"2019","unstructured":"Al-Hassiny A, Hussaini H, Milne T, Seo B, Rich A, Friedlander LT (2019) Vascularity and angiogenic signaling in the dentine-pulp complex of immature and mature permanent teeth. Eur Endod J 4(2):80\u201385. https:\/\/doi.org\/10.14744\/eej.2019.26349","journal-title":"Eur Endod J"},{"key":"6230_CR22","doi-asserted-by":"publisher","first-page":"4753645","DOI":"10.1155\/2020\/4753645","volume":"2020","author":"X Lv","year":"2020","unstructured":"Lv X, Li W, Fang Z, Xue X, Pan C (2020) Periodontal disease and age-related macular degeneration: a meta-analysis of 112,240 participants. Biomed Res Int 2020:4753645. https:\/\/doi.org\/10.1155\/2020\/4753645","journal-title":"Biomed Res Int"},{"issue":"S3","key":"6230_CR23","doi-asserted-by":"publisher","first-page":"S2238","DOI":"10.4103\/jpbs.jpbs_175_24","volume":"16","author":"M Parmar","year":"2024","unstructured":"Parmar M, Bhalodi A, Attwal HS, Kaur A, Osseiran R, Chavda HS (2024) Assessment of relation between periodontal disease and macular degeneration. J Pharm Bioallied Sci 16(S3):S2238\u2013S2240. https:\/\/doi.org\/10.4103\/jpbs.jpbs_175_24","journal-title":"J Pharm Bioallied Sci"},{"issue":"6","key":"6230_CR24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.oraloncology.2010.02.025","volume":"46","author":"JH Meurman","year":"2010","unstructured":"Meurman JH, Gr\u00f6nroos L (2010) Oral and dental health care of oral cancer patients: hyposalivation, caries and infections. Oral Oncol 46(6):464\u2013467. https:\/\/doi.org\/10.1016\/j.oraloncology.2010.02.025","journal-title":"Oral Oncol"},{"issue":"1","key":"6230_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/prd.12318","volume":"82","author":"DT Graves","year":"2020","unstructured":"Graves DT, Ding Z, Yang Y (2020) The impact of diabetes on periodontal diseases. Periodontol 2000 82(1):214\u2013224. https:\/\/doi.org\/10.1111\/prd.12318","journal-title":"Periodontol 2000"},{"key":"6230_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.trsl.2021.05.001","volume":"236","author":"KI Ko","year":"2021","unstructured":"Ko KI, Sculean A, Graves DT (2021) Diabetic wound healing in soft and hard oral tissues. Transl Res 236:72\u201386. https:\/\/doi.org\/10.1016\/j.trsl.2021.05.001","journal-title":"Transl Res"},{"key":"6230_CR27","unstructured":"Chi AC, Neville BW, Krayer JW, Gonsalves WC (2010) Oral manifestations of systemic disease. Am Fam Physician 82(11):1381\u20131388"},{"issue":"6","key":"6230_CR28","first-page":"1445","volume":"152","author":"NN Nissen","year":"1998","unstructured":"Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA (1998) Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 152(6):1445\u20131452","journal-title":"Am J Pathol"},{"issue":"4","key":"6230_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/annrheumdis-2020-218304","volume":"80","author":"S Menegatti","year":"2021","unstructured":"Menegatti S, Guillemot V, Latis E et al (2021) Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo. Ann Rheum Dis 80(4):475\u2013486. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218304","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"6230_CR30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"K Ghasemi Falavarjani","year":"2013","unstructured":"Ghasemi Falavarjani K, Nguyen QD (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye 27(7):787\u2013794. https:\/\/doi.org\/10.1038\/eye.2013.107","journal-title":"Eye"},{"issue":"5","key":"6230_CR31","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK (2014) Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26(5):605\u2013622. https:\/\/doi.org\/10.1016\/j.ccell.2014.10.006","journal-title":"Cancer Cell"},{"issue":"11","key":"6230_CR32","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.adaj.2022.07.009","volume":"153","author":"A Davila","year":"2022","unstructured":"Davila A, Magee R, France K (2022) A retrospective, single-center cohort study on complications after dental extractions in patients taking biologic agents. J Am Dent Assoc 153(11):1060\u20131069. https:\/\/doi.org\/10.1016\/j.adaj.2022.07.009","journal-title":"J Am Dent Assoc"},{"issue":"1","key":"6230_CR33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12891-018-2127-2","volume":"19","author":"S Takano","year":"2018","unstructured":"Takano S, Uchida K, Inoue G et al (2018) Vascular endothelial growth factor expression and their action in the synovial membranes of patients with painful knee osteoarthritis. BMC Musculoskelet Disord 19(1):204. https:\/\/doi.org\/10.1186\/s12891-018-2127-2","journal-title":"BMC Musculoskelet Disord"},{"issue":"5","key":"6230_CR34","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/jbmr.2828","volume":"31","author":"JL Hamilton","year":"2016","unstructured":"Hamilton JL, Nagao M, Levine BR, Chen D, Olsen BR, Im H (2016) Targeting VEGF and its receptors for the treatment of osteoarthritis and associated pain. J Bone Min Res 31(5):911\u2013924. https:\/\/doi.org\/10.1002\/jbmr.2828","journal-title":"J Bone Min Res"},{"issue":"7","key":"6230_CR35","doi-asserted-by":"publisher","first-page":"10775","DOI":"10.18632\/oncotarget.14615","volume":"8","author":"RP Hulse","year":"2017","unstructured":"Hulse RP (2017) Role of VEGF-A in chronic pain. Oncotarget 8(7):10775\u201310776. https:\/\/doi.org\/10.18632\/oncotarget.14615","journal-title":"Oncotarget"}],"container-title":["Clinical Oral Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-025-06230-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00784-025-06230-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-025-06230-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T04:59:08Z","timestamp":1742705948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00784-025-06230-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["6230"],"URL":"https:\/\/doi.org\/10.1007\/s00784-025-06230-7","relation":{},"ISSN":["1436-3771"],"issn-type":[{"type":"electronic","value":"1436-3771"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no financial or non-financial conflict of interest and no receipt of funds in connection with the preparation of this manuscript or the data included.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"151"}}